Skip to content
Gyre Therapeutics
Primary Menu
About
Overview
Management Team
Board of Directors
Science
Overview
Hydronidone
MASH
Other Disease Areas
Publications
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Contact
Pharmacokinetics of Subcutaneously Administered CB 2679D/ISU304 in minipig compared with BeneFIX
Post navigation
Previous:
Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered Marzeptacog Alfa (Activated) in Hemophilia dogs
Next:
Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered CB2679D/ISU304 in Hemophilia B Dogs
X
Previous
Next
